← Back to Clinical Trials
Recruiting NCT06388668

NCT06388668 Lipid Testing After Myocardial Infarction at the Montreal Heart Institute

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06388668
Status Recruiting
Phase
Sponsor Montreal Heart Institute
Condition Dyslipidemias
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-06-01
Primary Completion 2026-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Lipid panel

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-06-01 with a primary completion date of 2026-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization. It will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute. Every patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission. Thereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.

Eligibility Criteria

Inclusion Criteria: * Adult patients ≥18 years old * Hospitalized at the Cardiac Care Unit for Myocardial Infarction (either NSTEMI or STEMI) * Lipid panel performed on day 0 of admission * Willing to provide informed consent Exclusion Criteria: * None

Contact & Investigator

Central Contact

Suzy Otis

✉ suzy.otis@icm-mhi.org

📞 (514) 376-3330

Principal Investigator

Guillaume Marquis-Gravel, MD, MSc

PRINCIPAL INVESTIGATOR

Montreal Heart Institute

Frequently Asked Questions

Who can join the NCT06388668 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Dyslipidemias. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06388668 currently recruiting?

Yes, NCT06388668 is actively recruiting participants. Contact the research team at suzy.otis@icm-mhi.org for enrollment information.

Where is the NCT06388668 trial being conducted?

This trial is being conducted at Montreal, Canada, Montreal, Canada.

Who is sponsoring the NCT06388668 clinical trial?

NCT06388668 is sponsored by Montreal Heart Institute. The principal investigator is Guillaume Marquis-Gravel, MD, MSc at Montreal Heart Institute. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology